Azura Ophthalmics: Funding, Investors & Team (Sep 2026)
Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
Azura Ophthalmics has raised $20.0M across 2 funding rounds on record, the most recent a Grant announced in Sep 2022.
Azura Ophthalmics Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Azura Ophthalmics Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Azura Ophthalmics raised $20.0M in an undisclosed round announced in Oct 2020.
1.9 years later, a Grant was announced in Sep 2022 with no disclosed amount.
Azura Ophthalmics Founders and Leadership Team
Contact details for the Azura Ophthalmics team: 1 of 2 have an email address on file.
Start 14-day free trial →Azura Ophthalmics Funding Compared to Other Biotechnology Startups
Funded Startups Like Azura Ophthalmics in Biotechnology and Tel Aviv
Companies Similar to Azura Ophthalmics
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on…
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
Azura Ophthalmics Funding FAQs
What does Azura Ophthalmics do?
Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
How much funding has Azura Ophthalmics raised?
Azura Ophthalmics has raised $20.0M across 2 rounds on record.
When did Azura Ophthalmics last raise funding?
Azura Ophthalmics' most recent funding round on record was announced in Sep 2022. The amount was not disclosed.
Who founded Azura Ophthalmics?
FundedIQ lists Yair Alster (Founder) at Azura Ophthalmics.
Who is the CEO of Azura Ophthalmics?
Marc Gleeson is listed as CEO at Azura Ophthalmics.
Where is Azura Ophthalmics headquartered?
Azura Ophthalmics is based in Tel Aviv, Israel.
How many employees does Azura Ophthalmics have?
Azura Ophthalmics is in the 1-10 employee band.
About FundedIQ's Azura Ophthalmics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Azura Ophthalmics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.